CETTA, ILARIA
 Distribuzione geografica
Continente #
NA - Nord America 113
EU - Europa 81
AS - Asia 60
AF - Africa 1
SA - Sud America 1
Totale 256
Nazione #
US - Stati Uniti d'America 112
IT - Italia 42
CN - Cina 28
SG - Singapore 18
SE - Svezia 13
RU - Federazione Russa 9
FI - Finlandia 7
IN - India 5
TR - Turchia 4
DE - Germania 3
JP - Giappone 3
BG - Bulgaria 2
HK - Hong Kong 2
IE - Irlanda 2
AR - Argentina 1
CA - Canada 1
CH - Svizzera 1
GH - Ghana 1
NL - Olanda 1
UA - Ucraina 1
Totale 256
Città #
New York 24
Milan 13
Singapore 12
Ashburn 11
Boardman 10
Florence 8
Shanghai 6
Lappeenranta 4
Ankara 3
Coimbatore 3
Dallas 3
Helsinki 3
Lawrence 3
Perugia 3
Princeton 3
Washington 3
Beijing 2
Bologna 2
Dublin 2
Hong Kong 2
Jiaxing 2
Los Angeles 2
Moscow 2
San Cipriano d'Aversa 2
Sofia 2
Tokyo 2
Xi'an 2
Amsterdam 1
Buenos Aires 1
Falls Church 1
Ferrara 1
Foshan 1
Hachenburg 1
Laurel 1
Macerata 1
Newark 1
Nuremberg 1
Phoenix 1
Pune 1
Quanzhou 1
Rieti 1
Rome 1
Seattle 1
Shenzhen 1
Taizhou 1
Villarsiviriaux 1
Totale 153
Nome #
The effect of erenumab on brain network function in episodic migraine patients: a randomized, placebo-controlled clinical trial (RESET BRAIN) 36
Ocrelizumab extended-interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: a real-world experience 32
Myocardial infarction in a patient with migraine and triptan overuse treated with anti-CGRP receptor monoclonal antibody: a case report 31
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study 30
Comparison of efficacy and safety of erenumab between over and under 65-year-old refractory migraine patients: a pivotal study 29
Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study 26
Imaging the brain and vascular reactions to headache treatments: a systematic review 20
Stress in paediatric migraine: a trigger factor? 19
Stress related to COVID-19 pandemic as a trigger for disease activity in multiple sclerosis: a case report 18
Tracking the evolution of non-headache symptoms through the migraine attack 15
Correction to: Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study (Journal of Neurology, (2024), 271, 5, (2434-2443), 10.1007/s00415-023-12103-4) 13
Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study) (The Journal of Headache and Pain, (2022), 23, 1, (46), 10.1186/s10194-022-01396-x) 13
Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study) (The Journal of Headache and Pain, (2022), 23, 1, (46), 10.1186/s10194-022-01396-x) 12
Effectiveness and safety of monthly versus quarterly fremanezumab for migraine prevention: An Italian, multicenter, real‐life study 5
Efficacy and safety of anti-CGRP monoclonal antibodies for chronic migraine prophylaxis in patients treated with botulinum toxin A: A prospective monocentric study 3
Totale 302
Categoria #
all - tutte 2.795
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.795


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211 0 0 0 0 0 1 0 0 0 0 0 0
2021/20228 0 1 1 0 0 0 0 0 0 0 5 1
2022/202352 8 6 7 0 3 3 2 2 3 0 3 15
2023/2024161 7 16 16 14 13 27 3 16 4 4 19 22
2024/202580 24 6 19 14 17 0 0 0 0 0 0 0
Totale 302